Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate<i>Versus</i>Risedronate Over Two Years
Sydney Lou Bonnick(University of North Texas), Anne E. de Papp, Michael R. McClung(Bone Health and Osteoporosis Foundation), Marc C. Hochberg(University of Maryland, Baltimore), Sherri‐Ann M. Burnett‐Bowie(Harvard University), Risa Kagan(University of California, San Francisco), Erluo Chen, Desmond Thompson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anthony Sebba(Carolina Arthritis Associates), Kenneth G. Saag(University of Alabama at Birmingham), Douglas P. Kiel(Beth Israel Deaconess Medical Center)
Cited by 144
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates
|The Journals of Gerontology Series A|2014|2.5k